If an overdose is happening now in the United States, stop reading and call Poison Control at 1-800-222-1222, or 911 if symptoms are severe. The questions below belong to a conversation that happens afterward, or before anything goes wrong. They cover what the clinician needs to know, what the next several days involve, and how the error gets prevented.
Reviewed by Dr. Mark Ghalili, MD, Regenerative Medicine
Before the questions, the emergency route
Poison Control answers around the clock at no cost and decides whether a case can be observed at home or needs a facility. Tirzepatide labeling directs readers to that same line or a medical toxicologist and describes management as supportive treatment matched to the patient’s signs. There is no antidote, and nothing on this page is a triage tool. A scheduled discussion is a different exercise from an emergency, and mixing them costs time that matters.
The details a clinician will want first
Most of the useful information sits on the packaging rather than in memory. Bringing the pen, box, or vial to the appointment answers half the questions before they are asked.
| What to bring or state | Why the clinician asks | What a complete answer sounds like |
|---|---|---|
| Product name and source | Brand tirzepatide and compounded preparations differ in what can be assumed | A named brand pen, or a named compounding pharmacy |
| Concentration on the label | Compounded concentration is not standardized between pharmacies | The printed strength, read from the vial rather than recalled |
| Device type | Fixed-dose pens and vial-plus-syringe fail in different ways | Single-dose pen, multi-dose pen, or vial and syringe |
| Timing of the injection | Half-life near five days shapes the observation window | Date and approximate hour |
| Every other medication | Insulin and sulfonylureas change the hypoglycemia picture | A current list, including anything taken occasionally |
| Any other GLP-1 product in the house | Duplicate therapy and mixed products appear in error reports | Yes or no, with names |
Questions about what just happened
Ask what the clinician thinks was actually delivered, and how confident they are, because with a compounded preparation the answer may be a range rather than a number. Ask whether the symptoms so far match what they expect from that exposure, or whether something else may be going on. Ask what would change the plan, in concrete terms, so there is a named trigger for calling back rather than a vague instruction to monitor.
Ask whether Poison Control was contacted and whether a case number exists. Poison centers follow cases to a known outcome, and a case already in their system carries context that a new call would have to rebuild.
A question worth settling early is where the intended dose is written down, because a fixed reference speeds every later exchange. Approved labeling states the brand steps; among telehealth outfits the level of detail varies widely. Some, HealthRX among providers like Ro and Henry Meds, post a tirzepatide schedule a patient can review beforehand, turning a vague recollection into a specific figure a clinician can work from.
Questions about the days ahead
Ask how long the observation period runs and why. The answer should reference the drug’s persistence rather than the symptoms alone. Ask what the plan is for eating and drinking while appetite is suppressed, since intake is the practical measure of whether home management is working. For anyone on insulin or a sulfonylurea, ask specifically whether those medications need adjusting and who makes that change, because labeling flags that combination as the situation where lowering the other agent may be necessary.
Ask what happens to the next scheduled injection. That is a clinical decision built on what was already absorbed, and it should be stated explicitly rather than left implied. Ask who is reachable after hours during the follow-up window, and by what method.
Questions about preventing a repeat
This is the part most appointments skip, and it is where the evidence points. Analysis of cases reported to United States poison centers found that therapeutic errors accounted for roughly 80 percent of single-substance exposures involving this drug class. A single-center review reached a similar conclusion, with unintentional therapeutic errors behind about 69 percent of calls. These are supply and instruction failures far more often than they are patient carelessness.
Ask whether a fixed-dose device is available instead of a vial and syringe, and what that changes about cost. Ask whether the concentration of a compounded product will stay the same between refills, and how a change would be communicated. Ask for a written plan for a missed injection, in advance, since a published case series traced unintentional overdoses at initiation to gaps in both patient and prescriber knowledge. Ask whether anyone else in the household uses a similar pen, since labeling now carries an explicit instruction never to share a pen between patients.
Questions worth asking a prescribing service in advance
The structure of the service determines what happens on a bad day more than the prescription does. A primary care or endocrinology practice keeps one chart and a nurse line. Manufacturer channels such as LillyDirect and NovoCare route clinical questions back to the original prescriber. Telehealth services including Ro, Hims & Hers, LifeMD, and FormBlends differ in whether messages reach a clinician, whether the same clinician handles a returning case, and whether the concentration of a compounded preparation is stated in writing rather than on request. Asking those three questions at signup takes a few minutes and is worth more than any comparison of monthly cost.
Frequently asked questions
Is it worth asking whether the amount injected was dangerous?
Ask it, but expect a qualified answer. Individual response varies, and with a compounded product the delivered amount may not be known precisely. What the clinician can describe is the expected course, the features that would change the plan, and how long the observation window should run.
What should be asked if the product came from a compounding pharmacy?
Ask for the pharmacy name, the concentration on the label, and whether that concentration has changed between refills. Compounded tirzepatide is not FDA-approved and strength is not standardized across pharmacies, so a preparation that looks identical to the last one may not deliver the same amount.
How should the missed-dose question be raised?
Ask for it in writing before it is needed, covering how long a delay is acceptable and what to do when the timing is uncertain. Improvised catch-up after a missed injection is a documented route to duplicate administration, and a plan agreed in advance removes the guesswork.
Should other household members be part of the conversation?
Often yes. Poison center data include exposures among children as well as adults, and pens stored in shared spaces are part of that pattern. Asking how the medication should be stored, and who else could reach it, belongs in the same appointment as the dosing discussion.
What is a reasonable question about restarting?
Ask what has to be true before treatment resumes, and what would make the clinician recommend a different medication or delivery method instead. That framing gets a specific answer, whereas asking when to restart tends to produce a date that ignores what caused the problem.
